Radionuclide-Drug Conjugates (RDCs)
All Product Categories
-
Radionuclide-Drug Conjugates (RDCs) Related Products (99)
Related Products (99)
-
Cetuximab (PBS)
0 ImagesCat. No.: HY-P9S0008Purity: 99.33%
-
p-SCN-Bn-DOTA
0 Imagesp-SCN-Bn-DOTA is a bifunctional chelating agent. p-SCN-Bn-DOTA can simultaneously chelate radionuclides and link monoclonal antibody for radioimmunoresearch of tumor.
-
Pentixafor
0 ImagesPentixafor is a cyclic pentapeptide ligand that targets CXCR4. Pentixafor is composed of the cyclic pentapeptide Pentixafor peptide cyclo(dTyr-dOrn(NMe)-R-Nal-G) (HY-P11451), a linker, and a DOTA chelator. Pentixafor is capable of being labelled with 68Gallium (68Ga) for positron emission tomography (PET) imaging. Pentixafor can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
-
Tetraxetan
0 ImagesSynonyms: DOTATetraxetan (DOTA) is a macrocyclic chelating agent. Tetraxetan can form stable coordination complexes with a variety of metal ions (e.g., 68Ga, 111In, 177Lu). Tetraxetan can be conjugated with targeting molecules (e.g., RGD peptide, folic acid) to enable the complex to target specific biomolecules or cells. Tetraxetan can be used for imaging studies of tumors, including melanoma and folate receptor-positive tumors (e.g., cervical cancer) .
-
FAPI-mFS
0 ImagesFAPI-mFS is a selective fibroblast activation protein (FAP) inhibitor with an IC50 of 0.0014 μM against human FAP. Through its covalent binding property with FAP, FAPI-mFS enhances its uptake and retention time in cancer cells. When radiolabeled with 68Ga, FAPI-mFS serves as a PET/CT imaging agent with superior tumor-to-background tissue contrast and lesion detection capability. When radiolabeled with 177Lu or 225Ac, FAPI-mFS induces tumor regression and inhibition in preclinical models. FAPI-mFS can be used in studies related to cancer and radionuclide-conjugated drugs (RDC).
-
Cys-FAP targeting peptide for FXX489 TFA
0 ImagesCat. No.: HY-P10945BCys-FAP targeting peptide for FXX489 TFA is a version of the FAP-targeting peptide for FXX489 TFA that incorporates a Cys (cysteine) group. It can undergo conjugation reactions via the thiol group of the cysteine residue.
-
Tz-Ph-PEG4-NH-DOTA tetraTFA
0 ImagesCat. No.: HY-180447APurity: 98.01%Tz-Ph-PEG4-NH-DOTA (Compound 10) tetraTFA is a 1,2,4,5-tetrazine (Tz) derivative. Tz-Ph-PEG4-NH-DOTA tetraTFA can be used in PET imaging and tumor research.
-
DOTA-GPC3 targeting peptide 2
0 ImagesDOTA-GPC3 targeting peptide 2 (Sequence 30) is a RDC peptide targeting GPC3, with Kd of 0.3 nM. DOTA-GPC3 targeting peptide 2 is composed of DOTA and GPC3 targeting peptide 2. DOTA-GPC3 targeting peptide 2 can be labeled with radioactive elements.
-
Ethylenediaminetetra(methylenephosphonic acid)
0 ImagesSynonyms: EDTMPEthylenediaminetetramethylenephosphonic acid (EDTMP) is a bone-targeted chelating agent. Ethylenediaminetetramethylenephosphonic acid sodium‘s phosphonic acid groups possess a unique ability to bind with high affinity to hydroxyapatite in bone, and can form radioactive compounds with 153Sm and 177Lu. Ethylenediaminetetramethylenephosphonic acid is used to study palliative therapy for pain associated with multiple bone metastatic cancers.
-
HYNIC-PSMA
0 ImagesHYNIC-PSMA is a ligand for molecular imaging of tumors. Hynic-psma consists of two components: HYNIC (6-hydrazinonicotinamide) and PSMA (Prostate-Specific Membrane Antigen). HYNIC is a compound used to attach radioactive isotopes to targeted molecules, such as 188Re-HYNIC-PSMA. PSMA is a membrane antigen that is specifically expressed on the surface of prostate cancer cells. HYNIC-PSMA can be used in prostate cancer research. HYNIC-PSMA can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
-
HYNIC-iPSMA TFA
0 ImagesHYNIC-iPSMA TFA is a PSMA-targeted ligand for tumor molecular imaging, with a Ki value of 3.11 nM. HYNIC-iPSMA TFA consists of two components: HYNIC (6-hydrazinonicotinamide) and iPSMA (Inhibitor of Prostate-Specific Membrane Antigen). HYNIC serves as a chelating moiety to link radionuclides to the targeting molecule; iPSMA is a specific inhibitor that targets Prostate-Specific Membrane Antigen (PSMA). 68Ga-labeled iPSMA is used for prostate cancer detection via PET imaging, while the further developed 99mTc-EDDA/HYNIC-iPSMA TFA exhibits excellent specificity and sensitivity. HYNIC-iPSMA TFA can be used for the synthesis and research of radionuclide-conjugated drugs (RDC).
-
Betiatide
0 ImagesBetiatide, as a chelating agent for Technetium-99m (99mTc), is used to prepare 99mTc-MAG3 (mercaptoacetyltriglycine), a radiopharmaceutical for renal function imaging. Betiatide is used for the diagnosis of congenital and acquired abnormalities, renal failure, urinary tract obstructions, and calculi. Betiatide can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
-
MK-7337
0 ImagesMK-7337 is an α-synuclein ligand with an affinity of < 1 nM. MK-7337 labeled with 11C can be used as a PET tracer for neurodegenerative disorders like Parkinson’s disease imagination.
-
DOTA-cyclo(RGDfK)
0 ImagesDOTA-cyclo(RGDfK) is a radionuclide conjugate (RDC), which is capable of binding to a radionuclide. RDC has the ability to specifically target biomolecules and can be used in medical imaging or therapy.
-
SDM-8
0 ImagesSDM-8 is a difluoro-analog of UCB-J (HY-136873).SDM-8 shows high SV2A binding affinity with a Ki of 0.58 nM. SDM-8 can be used in the study of Alzheimer's disease.
-
Maleimide-DTPA
0 ImagesCat. No.: HY-W738256CAS No.: 180152-82-3Synonyms: MDTPAMaleimide-DTPA (MDTPA) is a maleimide-functionalized bifunctional chelator that enables site-specific conjugation via a thioether bond to single-domain antibody fragments (sdAb) containing free cysteine, and mediates 111In radiolabeling. DTPA-2Rs15d-HLC, formed by the conjugation of Maleimide-DTPA with anti-HER2 sdAb 2Rs15d-HLC, retains high affinity for HER2 with a Kd of 5.9 nM, and maintains targeting ability to HER2-positive cells and tumors after 111In labeling. Maleimide-DTPA can be used for radiotracer construction, SPECT molecular imaging, and HER2-positive tumor research.
-
DOTA-EB-TATE
0 ImagesCat. No.: HY-P10741CAS No.: 2151063-66-8DOTA-EB-TATE is composed of SST peptide derivative, DOTA-octreotate conjugated a common to an Evans blue analog (EB). DOTA-EB-TATE is a peptide drug conjugate (PDC) improves the pharmacokinetics of SSTR2 analogs and reduces PRRT toxicity. DOTA-EB-TATE can also be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
-
HQ-415
0 ImagesHQ-415 is a biologically active metal chelator related to Clioquinol (HY-14603), with an EC50 of 15 μM.
-
Polyamidoamine (20% in methanol)
0 ImagesCat. No.: HY-164657CAS No.: 153891-46-4Synonyms: PAMAMPolyamidoamine (PAMAM) (20% in methanol) is a new type of drug carrier that has drug encapsulation capabilities internally and biocompatibility on the surface, and can be used as a drug delivery system.
